Premas, Oramed and other shareholders, have formed Oravax Medical, which has received exclusive licenses from Oramed and Premas to develop oral COVID-19 vaccines. <\/p>\n\n\n\n
After a single dose of the Oravax COVID-19 capsule, efficacy was evident through antibody production in a pilot animal study. Oravax’s vaccine promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protect against viral infections and Immunoglobulin A (IgA) protects the respiratory and gastrointestinal tracts against infection. Premas’
protein-based VLP (virus-like particle) vaccine candidate creates triple protection against the SARS CoV-2 virus spike, membrane, and envelope targets. <\/p>\n\n\n\n
The vaccine candidate is also safe, efficacious and well-tolerated at normal to high doses, and generated high titres of neutralizing antibodies. <\/p>\n\n\n\n
The VLP is manufactured using Premas’ proprietary D-Crypt platform, which is highly scalable and can be manufactured on large scales. An oral Covid-19 vaccine that harnesses and combines the true potential of Premas’ D-Crypt technology platform with Oramed’s world-leading oral protein delivery platform, POD is an excellent example of collaboration and can rapidly advance into late-stage clinical trials, says Dr Prabuddha Kundu, Premas Biotech Co-Founder and Managing Director.<\/p>\n\n\n\n
Oramed’s experience and success in conducting Phase 2 and 3 oral protein trials position its program favourably in the race to find an effective oral Covid-19 vaccine that can be administered by anyone anywhere. The company is expected to share clinical data soon. An oral COVID19 vaccine would eliminate several barriers to rapid, wide-scale distribution, enabling people to take the vaccine themselves at home, says Nadav Kidron, CEO of Oramed.<\/p>\n","protected":false},"excerpt":{"rendered":"
Premas Biotech, a developer of novel biotherapeutic and vaccine candidates, with Oramed Pharmaceuticals, announced the development of an oral Covid-19 vaccine that has shown efficacy after a single dose. Premas, Oramed and other shareholders, have formed Oravax Medical, which has received exclusive licenses from Oramed and Premas to develop oral COVID-19 vaccines. After a single […]<\/p>\n","protected":false},"author":4,"featured_media":4225,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[16,45],"tags":[],"class_list":["post-4224","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19","category-new-launch"],"_links":{"self":[{"href":"https:\/\/dazzling-chebyshev.103-73-189-254.plesk.page\/index.php?rest_route=\/wp\/v2\/posts\/4224","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dazzling-chebyshev.103-73-189-254.plesk.page\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dazzling-chebyshev.103-73-189-254.plesk.page\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dazzling-chebyshev.103-73-189-254.plesk.page\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/dazzling-chebyshev.103-73-189-254.plesk.page\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4224"}],"version-history":[{"count":0,"href":"https:\/\/dazzling-chebyshev.103-73-189-254.plesk.page\/index.php?rest_route=\/wp\/v2\/posts\/4224\/revisions"}],"wp:attachment":[{"href":"https:\/\/dazzling-chebyshev.103-73-189-254.plesk.page\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4224"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dazzling-chebyshev.103-73-189-254.plesk.page\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4224"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dazzling-chebyshev.103-73-189-254.plesk.page\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}